Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRENGTH: Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia
2014-001069-28Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia, cardiac morbidity, sponsored by AstraZeneca. Started Jul 2014; status: terminated.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemiacardiac morbidity
Beyond the preview
Go deeper on 2014-001069-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001069-28.